Your session is about to expire
← Back to Search
Nivolumab +/- Ipilimumab for Lung Cancer
Study Summary
This trial is testing nivolumab with or without ipilimumab to see if it can treat patients with squamous cell lung cancer that has come back after previous treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have lung disease that causes symptoms or could affect lung toxicity treatment.I have not received treatments targeting immune checkpoints.I am not allergic to nivolumab or ipilimumab.I do not have HIV or AIDS.I haven't taken high-dose steroids or immunosuppressants in the last 2 weeks.I have a history of heart issues or am at risk, and have had heart function tests.I do not have severe heart disease or recent serious heart issues.I have had a heart condition and undergone tests like EKG and echocardiogram.You need to have certain blood tests done within a week before joining the study.I do not have active hepatitis B or C.I do not have an active autoimmune disease, except for allowed conditions like vitiligo or controlled hypothyroidism.
- Group 1: Arm II (nivolumab)
- Group 2: Arm I (nivolumab, ipilimumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Why is Laboratory Biomarker Analysis used?
"Cancerous neoplasms, unresectable melanomas, and other diseases that present with anti-angiogenic symptoms can be treated by Laboratory Biomarker Analysis."
What risks are inherent in Laboratory Biomarker Analysis?
"There is some evidence for efficacy and extensive safety data available for Laboratory Biomarker Analysis, so it received a score of 3."
Could you please explain the objectives of this clinical trial?
"The goal of this trial is to improve Investigator-assessed progression-free survival in Solid Tumors patients. Secondary outcomes include Objective Response Rate and Response rate in patients with measurable disease. Toxicity frequencies will also be monitored."
Is this trial offered at many locations within the city?
"The trial is based in Danbury Hospital, Christiana Gynecologic Oncology LLC, and Decatur Memorial Hospital but is also running in 100 other hospitals."
Would you please share if other research teams have looked into Laboratory Biomarker Analysis before?
"Currently, 801 clinical trials related to laboratory biomarker analysis are ongoing, with 87 of them in phase 3. Most of the trials for this topic are based in Pittsburgh, Pennsylvania, but there are 43516 locations across the globe conducting trials on this topic."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger